UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
UroGen Pharma (Nasdaq: URGN) will present at the Guggenheim Securities Healthcare Innovation Conference in Boston on November 11, 2025 at 10:30 AM ET. The company plans a presentation plus one-on-one investor meetings during the November 10–12, 2025 conference. Webcast and replay access will be available on UroGen’s investor relations website, with the replay online for approximately 90 days. The presentation focuses on recent corporate developments and investor engagement opportunities.
UroGen Pharma (Nasdaq: URGN) si presenterà al Guggenheim Securities Healthcare Innovation Conference a Boston il 11 novembre 2025 alle 10:30 AM ET. L'azienda prevede una presentazione più incontri individuali con gli investitori durante la conferenza dall'10 al 12 novembre 2025. L'accesso al webcast e alla replica sarà disponibile sul sito delle relazioni con gli investitori di UroGen, con la replica online per circa 90 giorni. La presentazione si concentrerà sugli ultimi sviluppi aziendali e sulle opportunità di coinvolgimento degli investitori.
UroGen Pharma (Nasdaq: URGN) participará en la Conferencia de Innovación en Salud de Guggenheim Securities en Boston el 11 de noviembre de 2025 a las 10:30 a. m. ET. La empresa planea una presentación y reuniones individuales con inversionistas durante la conferencia del 10 al 12 de noviembre de 2025. El acceso al webcast y la reproducción estará disponible en el sitio de relaciones con inversionistas de UroGen, y la reproducción estará en línea durante aproximadamente 90 días. La presentación se centra en los desarrollos recientes de la empresa y las oportunidades de participación de los inversionistas.
UroGen Pharma (나스닥: URGN)은 보스턴에서 열리는 구겐하임 증권 헬스케어 혁신 컨퍼런스에 2025년 11월 11일 동부 표준시 10:30 AM에 발표합니다. 회사는 2025년 11월 10일부터 12일까지 열리는 컨퍼런스 기간 동안 발표와 투자자 일대일 면담을 계획하고 있습니다. 웹캐스트 및 재생 접근은 투자자 관계 웹사이트에서 제공되며 재생은 약 90일 동안 온라인으로 이용 가능합니다. 발표 내용은 최근의 기업 발전 및 투자자 참여 기회에 중점을 둡니다.
UroGen Pharma (Nasdaq : URGN) participera au Guggenheim Securities Healthcare Innovation Conference à Boston le 11 novembre 2025 à 10h30 ET. L'entreprise prévoit une présentation ainsi que des réunions individuelles avec des investisseurs lors de la conférence du 10 au 12 novembre 2025. L'accès au webcast et à la rediffusion sera disponible sur le site des relations investisseurs d'UroGen, la rediffusion restant en ligne pendant environ 90 jours. La présentation portera sur les développements récents de l'entreprise et les opportunités d'engagement des investisseurs.
UroGen Pharma (Nasdaq: URGN) wird auf der Guggenheim Securities Healthcare Innovation Conference in Boston am 11. November 2025 um 10:30 Uhr ET auftreten. Das Unternehmen plant eine Präsentation sowie One-on-One-Investorengespräche während der Konferenz vom 10. bis 12. November 2025. Webcast- und Replay-Zugriff werden auf der Investor Relations-Website von UroGen verfügbar sein, wobei der Replay online für ca. 90 Tage zur Verfügung stehen wird. Die Präsentation konzentriert sich auf aktuelle Unternehmensentwicklungen und Möglichkeiten der Investoreneinbindung.
UroGen Pharma (ش.م.خ Nasdaq: URGN) ستقدم في مؤتمر Guggenheim Securities للابتكار في الرعاية الصحية في بوسطن في 11 نوفمبر 2025 الساعة 10:30 صباحاً بتوقيت شرق الولايات المتحدة. تخطط الشركة لعرض بالإضافة إلى اجتماعات فردية مع المستثمرين خلال مؤتمر 10–12 نوفمبر 2025. سيكون الوصول إلى البث المباشر وإعادة العرض متاحاً على موقع علاقات المستثمرين الخاص بـ UroGen، مع توفر إعادة العرض عبر الإنترنت لمدة تقرب من 90 يوماً. يركّز العرض على التطورات المؤسسية الأخيرة وفرص التواصل مع المستثمرين.
- None.
- None.
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Guggenheim Securities Healthcare Innovation Conference to take place on November 10-12, 2025.
Guggenheim Securities Innovation Conference
| Date / Time: | November 11, 2025 at 10:30 AM ET |
| Format: | Presentation and 1x1 investor meetings |
| Location: | Boston, MA |
| Webcast Link: | here |
Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
FAQ
When will UroGen (URGN) present at the Guggenheim Healthcare Innovation Conference?
How can investors watch the UroGen (URGN) presentation on November 11, 2025?
Will UroGen (URGN) hold investor meetings at the Guggenheim conference?
Where is the Guggenheim Securities Healthcare Innovation Conference where UroGen (URGN) will present?
How long will the UroGen (URGN) webcast replay be available after the November 11, 2025 presentation?
